Investor Presentaiton
Company Overview
About Us
Biond Biologics is a private
clinical-stage
biopharmaceutical
company, developing novel
immunotherapies for
cancer and a platform
enabling the intracellular
delivery of biologics
.
•
Our Innovation
At the forefront of research of
immune-evasion mechanisms
and its translation into novel
cancer therapeutics
Advanced in-house research
capabilities and access to
fresh tumor and blood
samples from cancer patients
A Transformative platform
enabling delivery of biologics
into cells, targeting
intracellular "undruggable"
proteins
The Team
• Proven track record for developing
novel drug candidates from scientific
concept to clinical trials
• Highly experienced in fund raising -
securing private and public funding
Successfully partnering with large
biopharma companies:
.
.
July 2015- Merck/CCAM; CM-24
mAb, phase-1 asset (M&A,
$95M upfront)
⚫ Jan 2021- Sanofi/Biond; BND-
22 mAb, IND ready asset
(Licensed, $125M upfront)
BIOND
BIOLOGICS
Biond Biologics Corporate Presentation | May 2021 | Non-confidential
2View entire presentation